Generic version of injectable acromegaly treatment launches in US
Click Here to Manage Email Alerts
Key takeaways:
- Teva Pharmaceuticals announced the launch of a generic form of Sandostatin LAR Depot.
- The medication is indicated for adults with acromegaly who had inadequate response to surgery or radiotherapy.
A generic version of a treatment for acromegaly is now available for adults in the U.S., according to an industry press release.
Teva Pharmaceuticals has launched generic octreotide acetate for injectable suspension. The medication is a generic form of Sandostatin LAR Depot (Novartis) and is now available for adults in the U.S. with acromegaly or those experiencing severe diarrhea with carcinoid syndrome. According to the press release, the medication is the first generic form of Sandostatin LAR Depot available in the U.S.
Octreotide acetate for injectable suspension is a medication for adults who tolerated and responded to initial octreotide acetate injection therapy. The treatment can be used as a long-term maintenance therapy for adults with acromegaly who had an inadequate response to surgery or radiotherapy, or cannot undergo surgery or radiotherapy to reduce growth hormone and insulin-like growth factor I levels.
The agent is also indicated for long-term treatment of severe diarrhea among adults with metastatic carcinoid tumors or those experiencing profuse watery diarrhea tied to vasoactive intestinal peptide secreting tumors. For adults with tumors, the effect of the medication on tumor size, growth rate and metastases development have not been determined, according to the release.
“With today’s launch of octreotide acetate for injectable suspension ... Teva is providing patients a new option for this important treatment,” Ernie Richardsen, senior vice president of U.S. commercial generics for Teva Pharmaceuticals, said in the release. “This first-to-market launch showcases Teva’s expertise in bringing complex generic formulations to market and demonstrates once again our ability to not only sustain a generics powerhouse, but also to bring value to patients and health care systems.”
Collapse
Read more about
Click Here to Manage Email Alerts